会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 8. 发明申请
    • DOUBLE-ACYLATED GLP-1 COMPOUNDS
    • 双酚A-GLP-1化合物
    • WO2015155151A1
    • 2015-10-15
    • PCT/EP2015/057442
    • 2015-04-07
    • NOVO NORDISK A/S
    • LINDEROTH, LarsKOFOED, JacobLAU, JesperBLOCH, PawGARIBAY, Patrick WilliamKODRA, János Tibor
    • A61K38/26C07K14/605
    • C07K14/605A61K38/00C07C235/20
    • The invention relates to a derivative of a GLP-1 peptide, which peptide comprises a first Lys residue at a position corresponding to position 36 of GLP-1(7-37) (SEQ ID NO:1), a second Lys residue at a position corresponding to position 37 of GLP-1(7-37) (SEQ ID NO : 1), and a maximum of seven amino acid changes as compared to GLP-1(7-37) (SEQ ID NO: 1); which derivative comprises two protractors attached to said first and second Lys residue, respectively, each via a linker; wherein the protractor is selected from : Chem. 1: HOOC-C 6 H 4 -0-(CH 2 ) y -CO-*, and Chem. 2: HOOC-(CH 2 ) x -CO-*, wherein y is an integer in the range of 8-11, and x is 12; and the linker comprises at least one of: Chem. 3: *-NH-CH(COOH)-(CH 2 ) 2 -CO-*, Chem. 4: *-NH-CH((CH 2 ) 2 -COOH)-CO-*, and/or Chem. 5: *-NH-(CH 2 ) 2 -[0-(CH 2 ) 2 ] k -0-[CH 2 ] n -CO-*, wherein k is an integer in the range of 1-5, and n is an integer in the range of 1-5; or a pharmaceutically acceptable salt, amide, or ester thereof. The invention also relates to the pharmaceutical uses thereof, such as for the treatment of diabetes and obesity, as well as to the GLP-1 peptides forming part of these derivatives which have Lys residues at positions 36 and 37 and no other Lys residues, and the GLP-1(9-37) fragments thereof. The invention furthermore relates to an intermediate product comprising 3-carboxyphenoxy-nonanoic acid with a protection group at the carboxy group of the nonanoic acid, optionally via a linker. The derivatives have a very good potency and a long half-life which makes them potentially useful for, e.g., oral administration.
    • 本发明涉及GLP-1肽的衍生物,该肽在对应于GLP-1(7-37)(SEQ ID NO:1)的位置36的位置处的第一个Lys残基, 与GLP-1(7-37)(SEQ ID NO:1)相比,对应于GLP-1(7-37)的位置37(SEQ ID NO:1)的位置和最多7个氨基酸的变化。 该衍生物分别包含分别连接到所述第一和第二Lys残基的两个量角器,每个通过连接体连接; 其中所述量角器选自:Chem。 1:HOOC-C6H4-0-(CH2)y-CO- *,和Chem。 2:HOOC-(CH 2)x -CO- *,其中y是8-11的整数,x是12; 并且所述接头包含以下至少一种:Chem。 3:* -NH-CH(COOH) - (CH 2)2 -CO- *, 4:* -NH-CH((CH 2)2 -COOH)-CO- *,和/或Chem。 5:* -NH-(CH2)2- [0-(CH2)2] k-0- [CH2] n-CO- *,其中k是1-5的整数,n是整数 在1-5的范围内; 或其药学上可接受的盐,酰胺或酯。 本发明还涉及其药学用途,例如用于治疗糖尿病和肥胖症,以及形成这些衍生物的一部分的GLP-1肽,其在36和37位具有Lys残基且没有其它Lys残基,以及 GLP-1(9-37)片段。 本发明还涉及包含3-羧基苯氧基 - 壬酸与壬酸羧基上的保护基团的中间产物,任选地通过连接体。 衍生物具有非常好的效力和长的半衰期,这使得它们可能用于例如口服给药。